2:07 PM
 | 
May 16, 2018
 |  BC Extra  |  Clinical News

Endocyte's radioligand therapy reduces PSA in CRPC patients

Newly released data showed that 177Lu-PSMA-617 from Endocyte Inc. (NASDAQ:ECYT) reduced prostate-specific antigen (PSA; KLK3) levels in a Phase II trial to treat metastatic castration-resistant prostate cancer. The data were released in an abstract ahead of the American Society of Clinical Oncology meeting in Chicago.

177Lu-PSMA-617 is a prostate-specific membrane antigen (PSMA; FOLH1; GCPII) directed radioligand therapy.

Among the investigator-sponsored trial's 50 patients, 177Lu-PSMA-617 reduced PSA levels by ≥50% in 31 patients, including 22 patients with a PSA decline of ≥80%. Median PSA progression-free survival (PFS) was 7 months and median overall survival (OS) was 12 months.

The trial, which was sponsored by the Peter MacCallum Cancer Centre, enrolled patients with PSMA-avid metastatic CRPC who progressed after conventional therapies to receive up to four cycles of 177Lu-PSMA-617 every six weeks.

This quarter, Endocyte plans to start the Phase III VISION trial of 177Lu-PSMA-617 to treat metastatic CRPC.

In October, ABX GmbH (Radeberg, Germany) granted Endocyte exclusive, worldwide rights to develop and commercialize the PSMA-targeting ligand PSMA-617 (see BioCentury Extra, Oct. 2, 2017).

Endocyte was up $0.45 to $12.56 on Wednesday. The data were released after market close.

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD